ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Calcium gluconate: Drug information

Calcium gluconate: Drug information
(For additional information see "Calcium gluconate: Patient drug information" and see "Calcium gluconate: Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: Canada
  • Calcium Sandoz
Pharmacologic Category
  • Calcium Salt;
  • Electrolyte Supplement, Oral;
  • Electrolyte Supplement, Parenteral
Dosing: Adult

Dosage guidance:

Dosing: Dosages are expressed in terms of the calcium gluconate salt (unless otherwise specified as elemental calcium). Dosages expressed in terms of the calcium gluconate salt are based on a solution concentration of 100 mg/mL (10%) containing 0.465 mEq (9.3 mg) elemental calcium per mL, except where noted. One gram of calcium gluconate salt is equal to 93 mg of elemental calcium.

Beta-blocker overdose

Beta-blocker overdose (off-label use): Based on limited data: IV: Initial: 60 mg/kg over 5 to 10 minutes (maximum: 3 to 6 g/dose); may repeat every 10 to 20 minutes for 3 to 4 additional doses or initiate a continuous infusion of 60 to 120 mg/kg/hour titrated to improve hemodynamic response (Ref).

Calcium channel blocker overdose

Calcium channel blocker overdose (off-label use): Based on limited data: IV: Initial: 60 mg/kg over 5 to 10 minutes (maximum: 3 to 6 g/dose); may repeat every 10 to 20 minutes for 3 to 4 additional doses or initiate a continuous infusion of 60 to 120 mg/kg/hour titrated to improve hemodynamic response (Ref). In one report, 18 g was administered over a 3-hour period (Ref). Note: Some recommend maintaining serum ionized calcium at a goal of twice normal (Ref).

Calcium replacement, during CRRT with citrate-based regional anticoagulation

Calcium replacement, during CRRT with citrate-based regional anticoagulation (off-label use) :

Intracircuit, posthemodialysis filter (returning to the patient) or IV through a separate central line: Ensure adequate systemic ionized calcium concentrations (drawn directly from the patient) prior to initiation of CRRT. During CRRT, use a calcium gluconate continuous infusion sliding scale to maintain systemic ionized calcium between ~3.6 to 5.2 mg/dL (~0.9 to 1.3 mmol/L); monitor systemic ionized calcium every 6 hours (or more frequently when indicated) (Ref). Refer to institutional protocols.

Cardiac arrest or cardiotoxicity in the presence of hypocalcemia or hypermagnesemia

Cardiac arrest or cardiotoxicity in the presence of hypocalcemia or hypermagnesemia: Note: Routine use in cardiac arrest is not recommended due to the lack of improved survival (Ref).

IV, Intraosseous: 1.5 to 3 g as a rapid bolus (Ref).

Hydrofluoric acid exposure

Hydrofluoric acid exposure (off-label use):

Systemic toxicity, prevention and treatment: Note: Profound and precipitous hypocalcemia may occur after exposure to higher hydrofluoric acid concentrations to even a small surface area (Ref). Additional treatment measures may be required (eg, magnesium) (Ref); consultation with a clinical toxicologist or poison control center is highly recommended.

IV: 2 g immediately or as soon as possible after exposure (before serum calcium level is known). Monitor serum calcium level; if serum calcium level is not within normal range, then give an additional 1 g, followed by 4 g over 1 hour, as needed, to maintain serum calcium levels (Ref).

Hydrofluoric acid burns, treatment:

Topical: 2.5% gel: After washing the affected area, apply liberally and allow the application to stay on the affected area for ≥30 minutes or for ≥15 minutes past the point of pain resolution, whichever is longer; cover and redress every 4 hours as needed. Note: Surgical gloves filled with gel are useful for hand burns (Ref). The use of gel-filled condom for penile exposure has been reported (Ref).

Note: If commercially available or extemporaneously compounded gel is unavailable, then topical application of wet compresses made with the 10% calcium gluconate IV solution may be used immediately following decontamination (Ref).

SUBQ (off-label route): 5% to 10% solution: 0.5 mL/cm2 of burned tissue (Ref). Infiltration should be carried 0.5 cm away from the margin of the injured tissue into the surrounding uninjured areas. Repeat if pain recurs. Local anesthesia may be required to perform procedure; pain resolution is the therapeutic endpoint and if a local anesthetic is utilized, it may be difficult to determine the success of therapy (Note: Never use calcium chloride for SUBQ injection as it may result in severe dermal necrosis).

Intra-arterial (off-label route): Add 1 g (10 mL of a 10% solution) to 50 mL of D5W. Infuse over 4 hours into the artery that provides the vascular supply to the affected area (Ref). Pain usually resolves by the end of the infusion; repeat if pain recurs. This intervention should be used only by those accustomed to this technique. Extreme care should be taken to avoid the extravasation. A poison information center or clinical toxicologist should be consulted prior to implementation.

IV (Bier block technique) (off-label route): Add 1.5 g (15 mL of a 10% solution) to 35 mL of NS and infuse over 2 minutes using a Bier block technique (Ref).

Hydrofluoric acid inhalational exposure, treatment: Inhalation (off-label route): 2.5% nebulization solution: Mix 1.5 mL of 10% calcium gluconate solution with 4.5 mL NS to make a 2.5% solution and administer via nebulization; repeat doses may be given after medical evaluation (Ref).

Hyperkalemia, severe/emergent

Hyperkalemia , severe/emergent (off-label use): Note: Use in patients with hyperkalemia-associated ECG changes or serum potassium >6.5 mEq/L (Ref). Stabilizes myocardial cell membrane without impacting plasma potassium concentrations; must combine with insulin/dextrose to decrease plasma potassium levels and other therapies to eliminate potassium from body (Ref). Perform continuous cardiac monitoring and obtain serial ECGs (Ref).

IV, Intraosseous: Initial: 1 to 2 g over 2 to 5 minutes; may repeat after 5 minutes if ECG changes persist or recur, then every 30 to 60 minutes as needed; usual initial dosage range: 1 to 3 g (Ref).

Hypocalcemia

Hypocalcemia:

Note: For use in patients with severe symptoms of hypocalcemia (eg, tetany, seizures, carpopedal spasm), ECG abnormalities (eg, QTc prolongation, arrhythmia), or an acute decrease in albumin-corrected serum calcium levels to <7 to 7.5 mg/dL (<1.75 to 1.87 mmol/L) when serious complications may occur if untreated (eg, following neck surgery). Should also be used in patients whose symptoms did not improve with or who can no longer take oral calcium. Correct concurrent hypomagnesemia if present (Ref). Do not use IV calcium as initial therapy in patients with chronic kidney disease who are asymptomatic or who have stable hypocalcemia with only mild symptoms (eg, paresthesias) (Ref).

Initial bolus dose(s): IV: Add 1 or 2 g (10 or 20 mL of a 10% solution) to 50 mL of D5W or NS (equivalent to ~90 or ~180 mg elemental calcium). Infuse over 10 to 20 minutes; may repeat bolus dose after 10 to 60 minutes if symptoms persist (Ref). If hypocalcemia is expected to persist (eg, hypoparathyroidism, pancreatitis), follow bolus dose(s) with a continuous IV calcium infusion (Ref). Note: In patients with chronic hypocalcemia who require IV therapy, may initiate therapy with a continuous IV infusion and omit bolus dosing (Ref).

Continuous infusion: IV : Add 11 g (110 mL of a 10% solution) to 890 mL of D5W or NS (equivalent to ~1 g elemental calcium in a final total volume of 1,000 mL). Initiate infusion at 50 to 100 mL/hour (equivalent to ~50 to 100 mg/hour of elemental calcium; adjust dose to maintain albumin-corrected serum calcium levels at the low end of normal. Initiate oral calcium and vitamin D supplements as soon as possible; once an effective oral regimen is achieved, taper IV calcium infusion slowly (eg, over 24 to 48 hours) (Ref).

Parenteral nutrition, maintenance requirement

Parenteral nutrition, maintenance requirement: Note: Expressed in terms of elemental calcium: IV: 10 to 15 mEq elemental calcium daily (Ref).

Radium-226 or strontium-90 internal contamination

Radium-226 or strontium-90 internal contamination (off-label use): IV: 2.5 g in 500 mL D5W over 4 to 6 hours once daily for up to 6 days; if possible, administer within 12 hours of radionuclide intake (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

Note: Do not use IV calcium as initial therapy in patients with chronic kidney disease who are asymptomatic or who have stable hypocalcemia with only mild symptoms (eg, paresthesias) (Ref).

Initiate with the lower limit of the dosage range (accumulation may occur with kidney impairment and subsequent doses may require adjustment based on serum calcium concentrations).

Dosing: Hepatic Impairment: Adult

No initial dosage adjustment necessary; subsequent doses should be guided by serum calcium concentrations. In patients in the anhepatic stage of liver transplantation, equal rapid increases in ionized concentrations occur suggesting that calcium gluconate does not require hepatic metabolism for release of ionized calcium (Ref).

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric

(For additional information see "Calcium gluconate: Pediatric drug information")

Dosage guidance:

Dosing: Dosages are expressed in terms of the calcium gluconate salt or elemental calcium; use caution.

1 gram calcium gluconate = 93 mg elemental calcium = 4.65 mEq calcium.

Calcium channel blocker toxicity, hypotension/conduction disturbances

Calcium channel blocker toxicity, hypotension/conduction disturbances: Infants, Children, and Adolescents: Dose expressed as calcium gluconate: IV: 60 mg/kg/dose administered over 30 to 60 minutes; maximum dose: 3,000 mg/dose (Ref); some experts recommend rapid administration (eg, infuse over 5 to 10 minutes) and recommend to repeat doses every 10 to 20 minutes up to 3 to 4 doses as needed (Ref); may also consider IV infusion (Ref). Note: Calcium chloride may provide a more rapid increase of ionized calcium in critically ill children. Calcium gluconate may be substituted if calcium chloride is not available or if administering through a peripheral line (Ref).

Hydrofluoric acid burns, treatment

Hydrofluoric acid burns, treatment: Limited data available: Children and Adolescents:

SUBQ: 5% to 10% solution: 0.5 mL/cm2 of burned tissue (Ref). Infiltration should be carried 0.5 cm away from the margin of the injured tissue into the surrounding uninjured areas. Repeat if pain recurs. Local anesthesia may be required to perform procedure; pain resolution is the therapeutic endpoint and if a local anesthetic is utilized, it may be difficult to determine the success of therapy. Note: Never use calcium chloride for subcutaneous injection.

Intra-arterial: Add 10 mL of a 10% solution to 50 mL of D5W. Infuse over 4 hours into the artery that provides the vascular supply to the affected area (Ref). Pain usually resolves by the end of the infusion; repeat if pain recurs. This intervention should be used only by those accustomed to this technique. Extreme care should be taken to avoid the extravasation. A poison information center or clinical toxicologist should be consulted prior to implementation.

Inhalation: 2.5% nebulization solution: Mix 1.5 mL of 10% calcium gluconate solution with 4.5 mL NS to make a 2.5% solution and administer via nebulization (Ref).

Hyperkalemia, adjunctive treatment

Hyperkalemia, adjunctive treatment:

Note: Calcium is administered for myocardium stabilization and prevention of arrhythmias; must be used in conjunction with therapy to shift potassium intracellularly and/or eliminate potassium.

Infants, Children, and Adolescents: Dose expressed as calcium gluconate: IV, Intraosseous: 60 to 100 mg/kg/dose; maximum dose: 2,000 mg/dose; may repeat if necessary (Ref).

Hypocalcemia, treatment

Hypocalcemia, treatment: Dose depends on clinical condition and serum calcium concentration; monitor closely.

Asymptomatic: Limited data available: Infants, Children, and Adolescents: Dose expressed as elemental calcium: Oral: 30 to 75 mg/kg/day in 4 to 5 divided doses (Ref). Note: In general, other oral calcium salts (eg, carbonate, glubionate) are a more preferable oral dosage form option in young pediatric patients; however, the 10% calcium gluconate injection may be given orally (Ref).

Mild to moderate symptoms:

IV Intermittent:

Infants, Children, and Adolescents <17 years: Dose expressed as calcium gluconate: IV: 29 to 60 mg/kg/dose every 6 hours (Ref).

Adolescents ≥17 years: Dose expressed as calcium gluconate: IV: 1,000 to 2,000 mg/dose every 6 hours (Ref).

Continuous IV Infusion:

Infants, Children, and Adolescents <17 years: Initial: Dose expressed as calcium gluconate: IV: 8 to 13 mg/kg/hour (Ref).

Adolescents ≥17 years: Initial: Dose expressed as calcium gluconate: IV: 5.4 to 21.5 mg/kg/hour (Ref).

Severe symptoms (eg, seizures, tetany): Infants, Children, and Adolescents: Dose expressed as calcium gluconate: IV, Intraosseous: 100 to 200 mg/kg/dose over 5 to 10 minutes, maximum dose: 1,000 to 2,000 mg/dose; may repeat as needed or follow with a continuous IV infusion of 8 to 32 mg/kg/hour (Ref).

Parenteral nutrition, maintenance calcium requirement

Parenteral nutrition, maintenance calcium requirement (Ref): Note: Dose expressed as elemental calcium:

Infants and Children ≤50 kg: IV: 0.5 to 4 mEq/kg/day as an additive to parenteral nutrition solution.

Children >50 kg and Adolescents: IV: 10 to 20 mEq/day as an additive to parenteral nutrition solution.

Rickets, treatment

Rickets, treatment: Limited data available: Note: Treatment should also include adequate vitamin D supplementation (Ref).

Infants, Children, and Adolescents: Dose expressed as elemental calcium: Oral: 30 to 75 mg/kg/day in 3 divided doses; begin at higher end of range and titrate downward over 2 to 4 weeks (Ref). Note: In general, other oral calcium salts (eg, carbonate, glubionate) are a more preferable oral dosage formulation option in young pediatric patients; however, the 10% calcium gluconate injection may be given orally (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

Initiate at the lowest dose of the recommended dosage range; monitor serum calcium concentrations closely. Accumulation may occur with renal impairment and subsequent doses may require adjustment based on serum calcium concentrations.

Dosing: Hepatic Impairment: Pediatric

No initial dosage adjustment necessary; subsequent doses should be guided by serum calcium concentrations. Hepatic function does not affect the availability of ionized calcium after calcium gluconate administration.

Adverse Reactions

The following adverse drug reactions are derived from product labeling unless otherwise specified.

Postmarketing:

Cardiovascular: Bradycardia, cardiac arrhythmia, decreased blood pressure, syncope, vasodilation

Dermatologic: Cutaneous calcification

Local: Inflammation at injection site, tissue necrosis at injection site

Contraindications

Hypercalcemia; concomitant use of IV calcium gluconate with ceftriaxone in neonates (≤28 days of age).

Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Warnings/Precautions

Concerns related to adverse effects:

• Extravasation: Parenteral calcium is a vesicant; ensure proper catheter or needle position prior to and during infusion. Avoid extravasation; adverse events from extravasation can be devastating (eg, profound tissue necrosis). Monitor the IV site closely.

• GI effects: Constipation, bloating, and gas are common with oral calcium supplements (especially carbonate salt).

Disease-related concerns:

• Hyperphosphatemia: Use with caution in patients with severe hyperphosphatemia as elevated levels of phosphorus and calcium may result in soft tissue and pulmonary arterial calcium-phosphate precipitation.

• Hypokalemia: Use with caution in patients with severe hypokalemia as acute rises in serum calcium levels may result in life-threatening cardiac arrhythmias.

• Hypomagnesemia: Hypomagnesemia is a common cause of hypocalcemia; therefore, correction of hypocalcemia may be difficult in patients with concomitant hypomagnesemia. Evaluate serum magnesium and correct hypomagnesemia (if necessary), particularly if initial treatment of hypocalcemia is refractory.

• Kidney stones (calcium-containing): Use caution when administering calcium supplements to patients with a history of kidney stones.

• Renal impairment: Use with caution in patients with chronic renal failure to avoid hypercalcemia; frequent monitoring of serum calcium and phosphorus is necessary.

Dosage form specific issues:

• Aluminum: The parenteral product may contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of >4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register 2002). See manufacturer's labeling.

• Appropriate product selection: Multiple salt forms of calcium exist; close attention must be paid to the salt form when ordering and administering calcium; incorrect selection or substitution of one salt for another without proper dosage adjustment may result in serious over or under dosing.

• IV administration: Avoid too-rapid IV administration (do not exceed 200 mg/minute in adults and 100 mg/minute in pediatric patients), unless patient is in cardiac arrest; may result in vasodilation, hypotension, bradycardia, arrhythmias, syncope, and cardiac arrest.

• Oral administration: Administering oral calcium with food and vitamin D will optimize calcium absorption.

• Topical administration: Avoid contact with eyes; not for oral administration.

• Tartrazine: Some products may contain tartrazine, which may cause allergic reactions in susceptible individuals.

Dosage Forms Considerations

1 g calcium gluconate = elemental calcium 93 mg = calcium 4.65 mEq = calcium 2.33 mmol

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Intravenous:

Generic: 10% (10 mL)

Solution, Intravenous [preservative free]:

Generic: 10% (10 mL, 50 mL, 100 mL); 1 g in NaCl 0.8% (100 mL); Calcium gluconate 1 g/50 mL in NaCl 0.675% (50 mL); Calcium gluconate 2 g/100 mL in NaCl 0.675% (100 mL)

Tablet, Oral:

Generic: 50 mg

Generic Equivalent Available: US

Yes

Pricing: US

Solution (Calcium Gluconate Intravenous)

10% (per mL): $0.58 - $0.65

Solution (Calcium Gluconate-NaCl Intravenous)

1GM/100ML 0.8% (per mL): $0.15

1GM/50ML 0.675% (per mL): $0.47

2GM/100ML 0.675% (per mL): $0.47

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Intravenous:

Generic: 10% (10 mL, 50 mL, 100 mL, 500 mL)

Administration: Adult

Oral: Administer with plenty of fluids with or following meals.

IV: For bolus or continuous infusion. Administer bolus slowly (not to exceed 200 mg/minute). For patients in cardiac arrest, administer as a rapid bolus via a central line or intraosseous route (Ref). For continuous infusions, adjust rate as needed based on serum calcium levels. Typical rates of administration may vary with indication; refer to institutional protocol. Not for IM administration.

Vesicant; ensure proper needle or catheter placement prior to and during IV infusion. Avoid extravasation.

Extravasation management:

Early/acute calcium extravasation: If extravasation occurs, stop infusion immediately; leave needle/cannula in place temporarily but do NOT flush the line; gently aspirate extravasated solution, then remove needle/cannula; elevate extremity; apply dry warm compresses; initiate hyaluronidase antidote (Ref).

Hyaluronidase: Intradermal or SUBQ: Inject a total of 1 to 1.7 mL (15 units/mL) as 5 separate 0.2 to 0.3 mL injections (using a tuberculin syringe) around the site of extravasation; if IV catheter remains in place, administer intravenously through the infiltrated catheter; may repeat in 30 to 60 minutes if no resolution (Ref).

Delayed calcium extravasation: Closely monitor site; most calcifications spontaneously resolve. However, if a severe manifestation of calcinosis cutis occurs, may initiate sodium thiosulfate antidote.

Sodium thiosulfate: IV: 12.5 g over 30 minutes, administered 3 times per week; may increase gradually to 25 g 3 times per week; monitor for non-anion gap acidosis, hypocalcemia, severe nausea (Ref).

Hydrofluoric acid exposure (off label):

Hydrofluoric acid burns, treatment:

SUBQ infiltration (off-label route): Using a 27- or 30-gauge needle, approach the wound from the distal point of injury and infiltrate directly into the affected dermis and subcutaneous tissue. The infiltration should be carried 0.5 cm away from the margin of the injured tissue into the surrounding uninjured areas (Ref). Avoid excessive administration, as it can cause compartment syndrome and further exacerbate tissue damage. Following subungual exposure, administer to the affected area via the lateral or volar route through the fat pad (under digital nerve block); administration may also require removal of the nailbed, splitting the distal nail from the nailbed, or trimming the nail to the nailbed to reach the affected area (Ref).

Topical: Massage into the affected area and cover with a dressing. For hand involvement, place hand in rubber glove filled with gel and bend fingers intermittently to ensure proper contact with gel. The use of gel-filled condom for penile exposure has been reported (Ref).

Intra-arterial (off-label route): Requires radiology to place an arterial catheter in an artery supplying blood to the area of exposure; infuse over four hours (Ref). This intervention should be used only by those accustomed to this technique. Care should be taken to avoid the extravasation. A poison information center or clinical toxicologist should be consulted prior to implementation.

Hydrofluoric acid inhalational exposure, treatment: Inhalation (off-label route): Mix 1.5 mL of 10% calcium gluconate solution with 4.5 mL NS to make a 2.5% solution and administer via nebulization (Ref).

Administration: Pediatric

Oral: Administer with plenty of fluids with or following meals. The 10% calcium gluconate injection may be administered orally in young pediatric patients (Ref).

Parenteral: Do not inject calcium salts IM or administer SUBQ since severe necrosis and sloughing may occur; extravasation of calcium can result in severe necrosis and tissue sloughing. Do not use scalp vein or small hand or foot veins for IV administration. Not for endotracheal administration.

Intermittent IV infusion: Vial must be diluted prior to administration; if using premix solution, do not dilute. Infuse dose slowly (not to exceed 100 mg/minute), except in emergency situations; administer through a secure IV line to avoid extravasation, dermal calcium deposits, or tissue necrosis. In acute situations of symptomatic hypocalcemia, infusions over 5 to 10 minutes have been described in pediatric patients (Ref).

Continuous IV infusion: Vial must be diluted prior to administration; if using premix solution, do not dilute. Adjust rate as needed based on serum calcium concentrations. Typical rates of administration may vary with indication; refer to institutional protocol.

Parenteral nutrition solution: Calcium-phosphate stability in parenteral nutrition solutions is dependent upon the pH of the solution, temperature, and relative concentration of each ion. The pH of the solution is primarily dependent upon the amino acid concentration. The higher the percentage amino acids the lower the pH, the more soluble the calcium and phosphate. Individual commercially available amino acid solutions vary significantly with respect to pH lowering potential and consequent calcium phosphate compatibility; consult product specific labeling for additional information.

Vesicant; ensure proper needle or catheter placement prior to and during IV infusion. Avoid extravasation.

Early/acute calcium extravasation: If acute extravasation occurs, stop infusion immediately and disconnect (leave needle/cannula in place); gently aspirate extravasated solution (do NOT flush the line); initiate hyaluronidase antidote (See Management of Drug Extravasations for more details); remove needle/cannula; apply dry cold compresses; elevate extremity (Ref).

Delayed calcium extravasation: If delayed extravasation suspected, closely monitor site; most calcifications spontaneously resolve. However, if a severe manifestation of calcinosis cutis occurs, may initiate sodium thiosulfate antidote (See Management of Drug Extravasations for more details) (Ref).

Use: Labeled Indications

Dietary supplement (oral only): Dietary calcium supplementation.

Hydrofluoric acid burns (Calgonate [topical]): Treatment of dermal hydrofluoric acid burns.

Hypocalcemia (IV only): Treatment of acute symptomatic hypocalcemia in adult and pediatric patients.

Use: Off-Label: Adult

Beta-blocker overdose; Calcium channel blocker overdose; Calcium replacement, during CRRT with citrate-based regional anticoagulation; Hyperkalemia, severe/emergent; Hydrofluoric acid exposure; Radium-226 or strontium-90 internal contamination

Medication Safety Issues
Sound-alike/look-alike issues:

Calcium gluconate may be confused with calcium glubionate, cupric sulfate

Administration issues:

Calcium gluconate may be confused with calcium chloride.

Confusion with the different intravenous salt forms of calcium has occurred. There is a threefold difference in the primary cation concentration between calcium gluconate (in which 1 g = 4.65 mEq [93 mg] of elemental Ca++) and calcium chloride (in which 1 g = 14 mEq [270 mg] of elemental Ca++).

Prescribers should specify which salt form is desired. To prevent medication errors, dosages should be expressed either as mg or grams of the salt form for most indications. Dosages expressed as mEq may be used for nutrition.

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Alpha-Lipoic Acid: Calcium Salts may decrease the absorption of Alpha-Lipoic Acid. Alpha-Lipoic Acid may decrease the absorption of Calcium Salts. Management: Separate administration of alpha-lipoic acid from that of any calcium-containing compounds by several hours. If alpha-lipoic acid is given 30 minutes before breakfast, then administer oral calcium-containing products at lunch or dinner. Risk D: Consider therapy modification

Baloxavir Marboxil: Polyvalent Cation Containing Products may decrease the serum concentration of Baloxavir Marboxil. Risk X: Avoid combination

Bictegravir: Calcium Salts may decrease the serum concentration of Bictegravir. Management: Bictegravir, emtricitabine, and tenofovir alafenamide can be administered with calcium salts under fed conditions, but coadministration with or 2 hours after a calcium salt is not recommended under fasting conditions. Risk D: Consider therapy modification

Bisphosphonate Derivatives: Polyvalent Cation Containing Products may decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral medications containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate. Risk D: Consider therapy modification

Cabotegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Cabotegravir. Management: Administer polyvalent cation containing products at least 2 hours before or 4 hours after oral cabotegravir. Risk D: Consider therapy modification

Calcium Acetate: Calcium Salts may enhance the adverse/toxic effect of Calcium Acetate. Risk X: Avoid combination

Calcium Channel Blockers: Calcium Salts may diminish the therapeutic effect of Calcium Channel Blockers. Risk C: Monitor therapy

Cardiac Glycosides: Calcium Salts may enhance the arrhythmogenic effect of Cardiac Glycosides. Risk C: Monitor therapy

CefTRIAXone: Calcium Salts (Intravenous) may enhance the adverse/toxic effect of CefTRIAXone. Ceftriaxone binds to calcium forming an insoluble precipitate. Management: Use of ceftriaxone is contraindicated in neonates (28 days of age or younger) who require (or are expected to require) treatment with IV calcium-containing solutions. In older patients, flush lines with compatible fluid between administration. Risk D: Consider therapy modification

Deferiprone: Polyvalent Cation Containing Products may decrease the serum concentration of Deferiprone. Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours. Risk D: Consider therapy modification

DOBUTamine: Calcium Salts may diminish the therapeutic effect of DOBUTamine. Risk C: Monitor therapy

Dolutegravir: Calcium Salts may decrease the serum concentration of Dolutegravir. Management: Administer dolutegravir at least 2 hours before or 6 hours after oral calcium. Administer dolutegravir/rilpivirine at least 4 hours before or 6 hours after oral calcium salts. Alternatively, dolutegravir and oral calcium can be taken together with food. Risk D: Consider therapy modification

Eltrombopag: Polyvalent Cation Containing Products may decrease the serum concentration of Eltrombopag. Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any polyvalent cation containing product. Risk D: Consider therapy modification

Elvitegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Elvitegravir. Management: Administer elvitegravir 2 hours before or 6 hours after the administration of polyvalent cation containing products. Risk D: Consider therapy modification

Estramustine: Calcium Salts may decrease the absorption of Estramustine. Management: Administer estramustine on an empty stomach, at least 1 hour before or 2 hours after the dose of an oral calcium supplement. If coadministered with calcium salts, monitor for decreased estramustine therapeutic effects. Risk D: Consider therapy modification

Levonadifloxacin: Calcium Salts may decrease the serum concentration of Levonadifloxacin. Risk X: Avoid combination

Multivitamins/Fluoride (with ADE): May increase the serum concentration of Calcium Salts. Calcium Salts may decrease the serum concentration of Multivitamins/Fluoride (with ADE). More specifically, calcium salts may impair the absorption of fluoride. Management: Avoid eating or drinking dairy products or consuming vitamins or supplements with calcium salts one hour before or after of the administration of fluoride. Risk D: Consider therapy modification

Multivitamins/Minerals (with ADEK, Folate, Iron): May increase the serum concentration of Calcium Salts. Risk C: Monitor therapy

PenicillAMINE: Polyvalent Cation Containing Products may decrease the serum concentration of PenicillAMINE. Management: Separate the administration of penicillamine and oral polyvalent cation containing products by at least 1 hour. Risk D: Consider therapy modification

Phosphate Supplements: Calcium Salts may decrease the absorption of Phosphate Supplements. Management: This applies only to oral phosphate and calcium administration. Administering oral phosphate supplements as far apart from the administration of an oral calcium salt as possible may be able to minimize the significance of the interaction. Risk D: Consider therapy modification

Quinolones: Calcium Salts may decrease the absorption of Quinolones. Of concern only with oral administration of both agents. Management: Consider administering an oral quinolone at least 2 hours before or 6 hours after the dose of oral calcium to minimize this interaction. Monitor for decreased therapeutic effects of quinolones during coadministration. Risk D: Consider therapy modification

Raltegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Raltegravir. Management: Administer raltegravir 2 hours before or 6 hours after administration of the polyvalent cations. Dose separation may not adequately minimize the significance of this interaction. Risk D: Consider therapy modification

Roxadustat: Polyvalent Cation Containing Products may decrease the serum concentration of Roxadustat. Management: Administer roxadustat at least 1 hour after the administration of oral polyvalent cation containing products. Risk D: Consider therapy modification

Strontium Ranelate: Calcium Salts may decrease the serum concentration of Strontium Ranelate. Management: Separate administration of strontium ranelate and oral calcium salts by at least 2 hours in order to minimize this interaction. Risk D: Consider therapy modification

Tetracyclines: Calcium Salts may decrease the serum concentration of Tetracyclines. Management: If coadministration of oral calcium with oral tetracyclines cannot be avoided, consider separating administration of each agent by several hours. Risk D: Consider therapy modification

Thiazide and Thiazide-Like Diuretics: May increase the serum concentration of Calcium Salts. Risk C: Monitor therapy

Thyroid Products: Calcium Salts may diminish the therapeutic effect of Thyroid Products. Management: Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased. Risk D: Consider therapy modification

Trientine: Polyvalent Cation Containing Products may decrease the serum concentration of Trientine. Management: Avoid concomitant use of trientine and polyvalent cations. If oral iron supplements are required, separate the administration by 2 hours. For other oral polyvalent cations, give trientine 1 hour before, or 1 to 2 hours after the polyvalent cation. Risk D: Consider therapy modification

Unithiol: May diminish the therapeutic effect of Polyvalent Cation Containing Products. Risk X: Avoid combination

Vitamin D Analogs: Calcium Salts may enhance the adverse/toxic effect of Vitamin D Analogs. Risk C: Monitor therapy

Pregnancy Considerations

Calcium crosses the placenta. The amount of calcium reaching the fetus is determined by maternal physiological changes (IOM 2011).

Calcium requirements are the same in pregnant patients and nonpregnant females (IOM 2011). Information related to use as an antidote in pregnancy is limited. In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant patients if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003). Medications used for the treatment of cardiac arrest in pregnancy are the same as in the nonpregnant patient. Doses and indications should follow current Advanced Cardiovascular Life Support guidelines. Appropriate medications should not be withheld due to concerns of fetal teratogenicity (Jeejeebhoy [AHA] 2015).

Breastfeeding Considerations

Calcium is present in breast milk.

The amount of calcium in breast milk is homeostatically regulated and not altered by maternal calcium intake. Calcium requirements are the same in lactating patients and nonlactating females (IOM 2011). According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.

Dietary Considerations

Dietary reference intake for calcium (IOM 2011):

0 to <6 months: Adequate intake: 200 mg elemental calcium/day.

6 to 12 months: Adequate intake: 260 mg elemental calcium/day.

1 to 3 years: Recommended dietary allowance (RDA): 700 mg elemental calcium/day.

4 to 8 years: RDA: 1,000 mg elemental calcium/day.

9 to 18 years: RDA: 1,300 mg elemental calcium/day.

19 to 50 years: RDA: 1,000 mg elemental calcium/day.

51 to 70 years: RDA:

Females: 1,200 mg elemental calcium/day.

Males: 1,000 mg elemental calcium/day.

>70 years: RDA: 1,200 mg elemental calcium/day.

Pregnancy/Lactating: RDA: Requirements are the same as in nonpregnant or nonlactating females.

Monitoring Parameters

IV: Serum calcium every 4 to 6 hours (during intermittent infusion), every 1 to 4 hours (during continuous infusion), or every 4 hours in patients with renal impairment; albumin, phosphate, and magnesium; vitals and ECG when appropriate. Monitor infusion site.

Calcium channel blocker overdose, beta-blocker overdose (off-label use): Monitor hemodynamic response; monitor serum ionized calcium levels every 30 minutes initially, then every 2 hours and maintain ionized calcium ~2 times the ULN; avoid severe hypercalcemia (ionized calcium levels >2 times ULN) (Kerns 2007).

Reference Range

Serum total calcium: 8.6 to 10.2 mg/dL (SI: 2.2 to 2.6 mmol/L). Note: Due to a poor correlation between the serum ionized calcium (free) and total serum calcium, particularly in states of low albumin or acid/base imbalances, direct measurement of ionized calcium is recommended.

Serum ionized calcium: 4.48 to 4.92 mg/dL (SI: 1.12 to 1.23 mmol/L).

In low albumin states, the corrected total serum calcium may be estimated by the following equation (assuming a normal albumin of 4 g/dL [SI: 40 g/L]).

Corrected total calcium (mg/dL) = measured total calcium (mg/mL) + 0.8 [4-measured serum albumin (g/dL)].

or

Corrected total calcium (mmol/L) = measured total calcium (mmol/L) + 0.02 [40-measured serum albumin (g/L)].

Mechanism of Action

Moderates nerve and muscle performance via action potential threshold regulation.

In hydrogen fluoride exposures, calcium gluconate provides a source of calcium ions to complex free fluoride ions and prevent or reduce toxicity; administration also helps to correct fluoride-induced hypocalcemia.

In patients with radium-226 (Ra-226) or strontium-90 internal contamination, calcium gluconate competes for bone binding sites and binds phosphate (REMM 2022).

Pharmacokinetics (Adult Data Unless Noted)

Absorption: Oral: Minimal unless chronic, high doses are given; predominantly in the duodenum and dependent on calcitriol and vitamin D; mean absorption of calcium intake varies with age (infants 60%, prepubertal children 28%, pubertal children 34%, adults 25%); during pregnancy, calcium absorption doubles; calcium is absorbed in soluble, ionized form; solubility of calcium is increased in an acidic environment (IOM 2011); decreased absorption occurs in patients with achlorhydria, renal osteodystrophy, steatorrhea, or uremia

Distribution: Primarily in skeleton (99%)

Protein binding: ~40%, primarily to albumin

Excretion: Primarily feces (75%; as unabsorbed calcium salts); urine (20%) (IOM 2011)

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AR) Argentina: Calcio gluconato | Gluconato calcio | Gluconato de calcio;
  • (AT) Austria: Calcilin;
  • (BD) Bangladesh: Calcium | Gultate;
  • (BR) Brazil: Gliconato de calcio | Gluconato de calcio;
  • (CN) China: Calcium glucon.co | Gai li de;
  • (CO) Colombia: Gluconato de calcio;
  • (DE) Germany: Ca d glukarat | Calciumgluconat fagron | Dobo | Dreisacal;
  • (EC) Ecuador: Gluconato de calcio | Gluconato de calcio Ecar;
  • (EE) Estonia: Calcii gluconas | Kaltsium glukonaat | Kaltsiumglukonaat;
  • (FI) Finland: Calcii gluconas;
  • (FR) France: Gluconate de calcium b.braun medical | Gluconate de calcium cooper;
  • (HU) Hungary: Calcimusc;
  • (IT) Italy: Calcio gluconato | Calcio gluconato monico;
  • (JP) Japan: Calcicol;
  • (KE) Kenya: Glucal;
  • (KR) Korea, Republic of: Daihan calcium gluconate | Jw calcium gluconate;
  • (LT) Lithuania: Calcii gluconas | Calcium gluconat | Calcium spofa;
  • (LV) Latvia: Calcii gluconas | Calcium gluconase | Kalcija glikonats;
  • (MX) Mexico: Bon ker;
  • (NZ) New Zealand: Calcium Gluconate B Braun | Radiance Boron;
  • (PE) Peru: Calcio gluconato | Glucal | Gluconato de calcio;
  • (PH) Philippines: Calcinate | Harson calcium gluconate;
  • (PL) Poland: Calcio gluconato | Calcium gluconicum;
  • (PT) Portugal: Gluconato de calcio Braun | Gluconato de calcio Labesfal;
  • (PY) Paraguay: Gluconato de calcio parafarma | Gluconato de calcio sanderson | Gluconato de calcio veinfar;
  • (RU) Russian Federation: Calcium gluconate lekt;
  • (TH) Thailand: Calcicon | Calcium;
  • (TN) Tunisia: Gluconate de calcium;
  • (TW) Taiwan: Calcium gluconated;
  • (UA) Ukraine: Calcii gluconas;
  • (UY) Uruguay: Gluconato de calcio | Gluconato de calcio icu vita | Gluconato de calcio sanderson;
  • (VE) Venezuela, Bolivarian Republic of: Gluconato de calcio;
  • (ZA) South Africa: Freeda calcium gluconate | Gulf calcium gluconate | Kalci-300
  1. 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 10.1: Life-Threatening Electrolyte Abnormalities. Circulation. 2005;112:IV121–5.
  2. Abrams SA, Committee on Nutrition. Calcium and vitamin D requirements of enterally fed preterm infants. Pediatrics. 2013;131(5):e1676-1683. [PubMed 23629620]
  3. Aluminum in large and small volume parenterals used in total parenteral nutrition. Fed Regist. 2002;67(244):77792-77793. To be codified at 21 CFR §201.323.
  4. American Society for Parenteral and Enteral Nutrition (ASPEN). Appropriate dosing for parenteral nutrition: ASPEN recommendations. https://www.nutritioncare.org/uploadedFiles/Documents/Guidelines_and_Clinical_Resources/PN%20Dosing%201-Sheet-Nov%202020-FINAL.pdf. Updated 2019. Accessed March 31, 2022.
  5. Ariyan CE, Sosa JA. Assessment and Management of Patients With Abnormal Calcium. Crit Care Med. 2004;32(4)(suppl):146-154. [PubMed 15064673]
  6. Bailey B. Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women? Birth Defects Res A Clin Mol Teratol. 2003;67(2):133-140. [PubMed 12769509]
  7. Balasubramanian S, Dhanalakshmi K, Amperayani S. Vitamin D deficiency in childhood-a review of current guidelines on diagnosis and management. Indian Pediatr. 2013;50(7):669-675. doi:10.1007/s13312-013-0200-3 [PubMed 23942432]
  8. Based on expert opinion.
  9. Bartlett JW, Walker PL. Management of calcium channel blocker toxicity in the pediatric patient. J Pediatr Pharmacol Ther. 2019;24(5):378-389. doi:10.5863/1551-6776-24.5.378 [PubMed 31598101]
  10. Bentur Y, Biran I, Miller B. Evaluation of the Efficacy of 1% Calcium Gluconate in the Treatment of Hydrofluoric Acid (HF) Eye Burn. Clin Toxicol. 1995;33(5):535.
  11. Bilezikian JP, Brandi ML, Cusano NE, et al. Management of hypoparathyroidism: present and future. J Clin Endocrinol Metab. 2016;101(6):2313-2324. doi:10.1210/jc.2015-3910 [PubMed 26938200]
  12. Burry LD, Tung DD, Hallett D, et al. Regional citrate anticoagulation for PrismaFlex continuous renal replacement therapy. Ann Pharmacother. 2009;43(9):1419-25. doi:10.1345/aph.1M182 [PubMed 19690224]
  13. Calcium gluconate injection (premixed bags) [prescribing information]. Lake Zurich, IL: Fresenius Kabi; March 2023.
  14. Calcium gluconate injection (vial) [prescribing information]. Lake Zurich, IL: Fresenius Kabi; July 2018.
  15. Calcium gluconate injection (premixed bag) [prescribing information]. Paramus, NJ: WG Critical Care LLC; June 2021.
  16. Calcium gluconate injection (premixed bag) [prescribing information]. Lake Zurich, IL: Fresenius Kabi; March 2023.
  17. Choe MSP, Lee MJ, Seo KS, et al. Application of calcium nebulization for mass exposure to an accidental hydrofluoric acid spill. Burns. 2020;46(6):1337-1346. doi:10.1016/j.burns.2020.02.015 [PubMed 32209280]
  18. Clase CM, Carrero JJ, Ellison DH, et al; Conference Participants. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2020;97(1):42-61. doi:10.1016/j.kint.2019.09.018 [PubMed 31706619]
  19. Dart RC, Goldfrank LR, Erstad BL, et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. Ann Emerg Med. 2018;71(3):314-325. doi:10.1016/j.annemergmed.2017.05.021 [PubMed 28669553]
  20. DeWitt CR, Walsman JC. Pharmacology, Pathophysiology and Management of Calcium Channel Blocker and Beta-Blocker Toxicity. Toxicol Rev. 2004;23(4):223-238. [PubMed 15898828]
  21. Dibbell DG, Iverson RE, Jones W, et al. Hydrofluoric Acid Burns of the Hand. J Bone Joint Surg Am. 1970;52(5):931-936. [PubMed 5479482]
  22. Edmondson S, Almquist TD. Iatrogenic hypocalcemic tetany. Ann Emerg Med. 1990;19(8):938-940. [PubMed 2372181]
  23. Eichenwald EC. Manual of Neonatal Care. 8th edition. Philadelphia, PA: Lippincott Williams & Wilkins; 2017.
  24. Fong J, Khan A. Hypocalcemia: updates in diagnosis and management for primary care. Can Fam Physician. 2012;58(2):158-162. [PubMed 22439169]
  25. French S, Subauste J, Geraci S. Calcium abnormalities in hospitalized patients. Southern Med J. 2012;105(4):231-237. [PubMed 22475676]
  26. Golden NH, Abrams SA; Committee on Nutrition. Optimizing bone health in children and adolescents. Pediatrics. 2014;134(4):e1229-e1243. doi:10.1542/peds.2014-2173 [PubMed 25266429]
  27. Goltzman D. Treatment of hypocalcemia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed March 9, 2022.
  28. Greenbaum LA. Vitamin D deficiency (rickets) and excess. In: Kliegman RM, St. Geme J, eds. Nelson Textbook of Pediatrics. 21st ed. Saunders Elsevier; 2020:chap. 64.
  29. Hatzifotis M, Williams A, Muller M, et al. Hydrofluoric Acid Burns. Burns. 2004;30(2):156-159. [PubMed 15019125]
  30. Heaney RP, Recker RR, Saville PD. Menopausal Changes in Calcium Balance Performance. J Lab Clin Med. 1978;92(6):953-963. [PubMed 739173]
  31. Howarth DM, Dawson AH, Smith AJ, et al. Calcium Channel Blocking Drug Overdose: An Australian Series. Hum Exp Toxicol. 1994;13(3):161-166. [PubMed 7909677]
  32. Hurst S, McMillan M. Innovative solutions in critical care units: extravasation guidelines. Dimens Crit Care Nurs. 2004;23(3):125-128. [PubMed 15192356]
  33. IOM (Institute of Medicine). Dietary Reference Intakes for Calcium and Vitamin D. The National Academies Press; 2011.
  34. Isbister GK. Continuous Calcium Chloride Infusion for Massive Nifedipine Overdose. Emerg Med J. 2002;19(4):355-357. [PubMed 12101159]
  35. Jain A, Agarwal R, Sankar MJ, Deorari A, Paul VK. Hypocalcemia in the newborn. Indian J Pediatr. 2010;77(10):1123-1128. [PubMed 20737250]
  36. Jeejeebhoy FM, Zelop CM, Lipman S, et al; American Heart Association Emergency Cardiovascular Care Committee, Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, Council on Cardiovascular Diseases in the Young, and Council on Clinical Cardiology. Cardiac Arrest in Pregnancy: A Scientific Statement From the American Heart Association. Circulation. 2015;132(18):1747-1773. doi:10.1161/CIR.0000000000000300 [PubMed 26443610]
  37. Kelly A, Levine MA. Hypocalcemia in the critically ill patient. J Intensive Care Med. 2013;28(3):166-177. doi:10.1177/0885066611411543 [PubMed 21841146]
  38. Kerns W 2nd. Management of beta-adrenergic blocker and calcium channel antagonist toxicity. Emerg Med Clin North Am. 2007;25(2):309-331. [PubMed 17482022]
  39. Kirkpatrick JJ, Burd DAR. An Algorithmic Approach to the Treatment of Hydrofluoric Acid Burns. Burns. 1995;21(7):495-499. [PubMed 8540974]
  40. Kirwan CJ, Hutchison R, Ghabina S, et al. Implementation of a simplified regional citrate anticoagulation protocol for post-dilution continuous hemofiltration using a bicarbonate buffered, calcium containing replacement solution. Blood Purif. 2016;42(4):349-355. doi:10.1159/000452755 [PubMed 27866200]
  41. Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010;122(18)(suppl 3):876-908. [PubMed 20956230]
  42. Konca Ç, Yıldızdaş RD, Sarı MY, Yükselmiş U, Horoz ÖÖ, Yılmaz HL. Evaluation of children poisoned with calcium channel blocker or beta blocker drugs. Turk Arch Ped. 2013;48:138-144.
  43. Koo WWK, Tsang RC. Calcium and magnesium homeostasis. In: MacDonald MG, Seshia MMK, eds. Avery's Neonatology - Pathophysiology and Management of the Newborn. 7th ed. Lippincott Williams & Wilkins; 2015:646-669.
  44. Krenzelok EP. Hydrofluoric acid exposures. In: Sullivan JB, Krieger GR, eds. Clinical Environmental Health and Toxic Exposures. 2nd ed. Lippincott Williams & Wilkins; 1999:798-806.
  45. Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS Guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2018:S0735-1097(18)38985-X. doi:10.1016/j.jacc.2018.10.044 [PubMed 30412709]
  46. Lam YM, Tse HF, Lau CP. Delayed Asystolic Cardiac Arrest After Diltiazem Overdose: Resuscitation With High Dose Intravenous Calcium. Chest. 2001;119(4):1280-1282. [PubMed 11296202]
  47. Lo SF. Reference intervals for laboratory tests and procedures. In: Kliegman RM, St. Geme J, eds. Nelson Textbook of Pediatrics. 21st ed. Saunders Elsevier; 2020:chap. 748.
  48. Love JN, Hanfling D, Howell JM. Hemodynamic effects of calcium chloride in a canine model of acute propranolol intoxication. Ann Emerg Med. 1996;28(1):1-6. [PubMed 8669723]
  49. Lüscher TF, Noll G, Stürmer T, Huser B, Wenk M. Calcium gluconate in severe verapamil intoxication. N Engl J Med. 1994;330(10):718-720. doi:10.1056/NEJM199403103301019 [PubMed 8107735]
  50. Lynch R, Wood EG, Neumayr TM. Fluid and electrolyte issues in pediatric critical illness. In: Fuhrman B, Zimmerman J, eds. Pediatric Critical Care. 5th ed. Elsevier Health; 2017:1007-1025.
  51. MacCara ME. Extravasation: a hazard of intravenous therapy. Drug Intell Clin Pharm. 1983;17(10):713-717. [PubMed 6628223]
  52. Martin TJ, Kang Y, Robertson KM, et al. Ionization and Hemodynamic Effects of Calcium Chloride and Calcium Gluconate in the Absence of Hepatic Function. Anesthesiology. 1990;73(1):62-65. [PubMed 2360741]
  53. McKee D, Thoma A, Bailey K, Fish J. A review of hydrofluoric acid burn management. Plast Surg (Oakv). 2014;22(2):95-98. [PubMed 25114621]
  54. Millard TP, Harris AJ, MacDonald DM. Calcinosis Cutis Following Intravenous Infusion of Calcium Gluconate. Br J Dermatol. 1999;140(1):184-186. [PubMed 10215803]
  55. Mimouni F, Tsang RC. Neonatal hypocalcemia: to treat or not to treat? (A review). J Am Coll Nutr. 1994;13(5):408-415. [PubMed 7836618]
  56. Mirtallo J, Canada T, Johnson D, et al. Safe Practices for Parenteral Nutrition. JPEN J Parenter Enteral Nutr. 2004;28(6):S39-S70. [PubMed 15568296]
  57. Misra M, Pacaud D, Petryk A, Collett-Solberg PF, Kappy M; Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics. 2008;122(2):398-417. doi:10.1542/peds.2007-1894 [PubMed 18676559]
  58. Mokhlesi B, Leikin JB, Murray P, et al. Adult Toxicology in Critical Care: Part II: Specific Poisonings. Chest. 2003;123(3):897-922. [PubMed 12628894]
  59. Mount DB. Treatment and prevention of hyperkalemia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 9, 2021.
  60. Munns CF, Shaw N, Kiely M, et al. Global consensus recommendations on prevention and management of nutritional rickets. Horm Res Paediatr. 2016;85(2):83-106. doi:10.1159/000443136 [PubMed 26741135]
  61. Nelson LS, Howland, MA, Lewin NA, et al, eds. Goldfrank's Toxicologic Emergencies, 11th ed. McGraw-Hill Education; 2019.
  62. Neumar RW, Otto CW, Link MS, et al. Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010;122(18)(suppl 3):729-767.
  63. Pai AB. Chapter 59: Disorders of Calcium and Phosphorus Homeostasis. Pharmacotherapy: A Pathophysiologic Approach. 8th ed. Talbert RL, DiPiro JT, Matzke GR, et al, eds. McGraw-Hill; 2011.
  64. Palsson R, Niles JL. Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding. Kidney Int. 1999;55(5):1991-1997. [PubMed 10231464]
  65. Panchal AR, Bartos JA, Cabañas JG, et al; Adult basic and advanced life support writing group. Part 3: adult basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2020;142(16)(suppl 2):S366-S468. doi:10.1161/CIR.0000000000000916 [PubMed 33081529]
  66. Pearigen PD, Benowitz NL. Poisoning Due to Calcium Antagonists: Experience With Verapamil, Diltiazem, and Nifedipine. Drug Saf. 1991;6(6):408-430. [PubMed 1793522]
  67. Perkins CM. Serious verapamil poisoning: treatment with intravenous calcium gluconate. Br Med J. 1978;2(6145):1127. [PubMed 709264]
  68. Pertoldi F, D'Orlando L, Mercante WP. Electromechanical dissociation 48 hours after atenolol overdose: usefulness of calcium chloride. Ann Emerg Med. 1998;31(6):777-781. [PubMed 9624322]
  69. Pu Q, Qian J, Tao W, Yang A, Wu J, Wang Y. Extracorporeal membrane oxygenation combined with continuous renal replacement therapy in cutaneous burn and inhalation injury caused by hydrofluoric acid and nitric acid. Medicine (Baltimore). 2017;96(48):e8972. doi:10.1097/MD.0000000000008972 [PubMed 29310404]
  70. Ramoska EA, Spiller HA, Winter M, Borys D. A one-year evaluation of calcium channel blocker overdoses: toxicity and treatment. Ann Emerg Med. 1993;22(2):196-200. [PubMed 8427431]
  71. Recker RR. Calcium Absorption and Achlorhydria. N Engl J Med. 1985;313(2):70-73. [PubMed 4000241]
  72. Refer to manufacturer's labeling.
  73. Reynolds PM, MacLaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. Pharmacotherapy. 2014;34(6):617-632. [PubMed 24420913]
  74. Rigo J, Pieltain C, Salle B, Senterre J. Enteral calcium, phosphate and vitamin D requirements and bone mineralization in preterm infants. Acta Paediatrica. 2007;96:969-974. [PubMed 17577338]
  75. Roberts JR, Merigian KS. Acute Hydrofluoric Acid Exposure. Am J Emerg Med. 1989;7(1):125-126. [PubMed 2914038]
  76. Root AW. Disorders of mineral metabolism II. Abnormalities of mineral homeostasis in the newborn, infant, child, and adolescent. In: Sperling MA, ed. Pediatric Endocrinology. 5th ed. Elsevier; 2020:chap. 20.
  77. Root AW, Harrison HE. Recent advances in calcium metabolism. II. Disorders of calcium homeostasis. J Pediatr. 1976;88(2):177-199. [PubMed 765441]
  78. Salhanick SD, Shannon MW. Management of Calcium Channel Antagonist Overdose. Drug Saf. 2003;26(2):65-79. [PubMed 12534324]
  79. Schmidt MJ, Bryant SM. Hydrofluoric Acid Burn to Penis. Clin Toxicol (Phila). 2007;45(6):732. [PubMed 17849253]
  80. Schneider AG, Journois D, Rimmelé T. Complications of regional citrate anticoagulation: accumulation or overload? Crit Care. 2017;21(1):281. doi:10.1186/s13054-017-1880-1 [PubMed 29151020]
  81. Scott SM, Ladenson JH, Aguanna JJ, Walgate J, Hillman LS. Effect of calcium therapy in the sick premature infant with early neonatal hypocalcemia. J Pediatr. 1984;104(5):747-751. [PubMed 6716222]
  82. Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs used to treat pediatric emergencies. Pediatrics. 2020;145(1):e20193450. doi:10.1542/peds.2019-3450 [PubMed 31871244]
  83. Smolders EJ, Benoist GE, Smit CCH, Ter Horst P. An update on extravasation: basic knowledge for clinical pharmacists. Eur J Hosp Pharm. 2020;28(3):165-167. doi:10.1136/ejhpharm-2019-002152 [PubMed 32341081]
  84. St-Onge M, Anseeuw K, Cantrell FL, et al. Experts consensus recommendations for the management of calcium channel blocker poisoning in adults. Crit Care Med. 2017;45(3):e306-e315. doi:10.1097/CCM.0000000000002087 [PubMed 27749343]
  85. Stefanos SS, Kiser TH, MacLaren R, Mueller SW, Reynolds PM. Management of noncytotoxic extravasation injuries: a focused update on medications, treatment strategies, and peripheral administration of vasopressors and hypertonic saline. Pharmacotherapy. 2023;43(4):321-337. doi:10.1002/phar.2794 [PubMed 36938775]
  86. Su MK. Hyrdofluoric acid and fluorides. Goldfrank's Toxicologic Emergencies. 11th ed. Nelson LS, Howland MA, Lewin NA, Smith SW, Hoffman RS, eds. McGraw Hill; 2019.
  87. Tolwani AJ, Prendergast MB, Speer RR, Stofan BS, Wille KM. A practical citrate anticoagulation continuous venovenous hemodiafiltration protocol for metabolic control and high solute clearance. Clin J Am Soc Nephrol. 2006;1(1):79-87. doi:10.2215/CJN.00040505 [PubMed 17699194]
  88. Trujillo M, Guerrero J, Fragachan C, et al. Pharmacologic Antidotes in Critical Care Medicine: A Practical Guide for Drug Administration. Crit Care Med. 1998;26(2):377-391.
  89. Turner J, Gittoes N, Selby P; Society for Endocrinology Clinical Committee. Society for Endocrinology endocrine emergency guidance: emergency management of acute hypocalcaemia in adult patients. Endocr Connect. 2016;5(5):G7-G8. doi:10.1530/EC-16-0056 [PubMed 27935815]
  90. Upfal M, Doyle C. Medical management of hydrofluoric acid exposure. J Occup Med. 1990;32(8):726-731. [PubMed 2401930]
  91. US Department of Health and Human Services (HHS) Radiation Emergency Medical Management (REMM). Managing internal radiation contamination. https://remm.hhs.gov/int_contamination.htm#blockingagents_2. Updated February 17, 2022. Accessed February 21, 2022.
  92. Vallentin MF, Granfeldt A, Meilandt C, et al. Effect of intravenous or intraosseous calcium vs saline on return of spontaneous circulation in adults with out-of-hospital cardiac arrest: a randomized clinical trial. JAMA. 2021;326(22):2268-2276. doi:10.1001/jama.2021.20929 [PubMed 34847226]
  93. Vance MV, Curry SC, Kunkel DB, et al. Digital Hydrofluoric Acid Burns: Treatment With Intraarterial Calcium Infusion. Ann Emerg Med. 1986;15(8):890-896. [PubMed 3740574]
  94. Vanden Hoek TL, Morrison LJ, Shuster M, et al. Part 12: Cardiac Arrest in Special Situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010;122(18)(suppl 3):829-861. [PubMed 20956228]
  95. Vuralli D. Clinical approach to hypocalcemia in newborn period and infancy: who should be treated?. Int J Pediatr. 2019;2019:4318075. doi:10.1155/2019/4318075 [PubMed 31320908]
  96. Wang X, Zhang Y, Ni L, et al. A review of treatment strategies for hydrofluoric acid burns: current status and future prospects. Burns. 2014;40(8):1447-1457. doi:10.1016/j.burns.2014.04.009 [PubMed 24946967]
  97. Wills MR, Lewin MR. Plasma Calcium Fractions and the Protein-Binding of Calcium in Normal Subjects and in Patients With Hypercalcaemia and Hypocalcaemia. J Clin Pathol. 1971;24(9):856-866. [PubMed 5139991]
  98. Worthley LI, Phillips PJ. Intravenous Calcium Salts. Lancet. 1980;2(8186):149.
  99. Wu ML, Deng JF, Fan JS. Survival after hypocalcemia, hypomagnesemia, hypokalemia and cardiac arrest following mild hydrofluoric acid burn. Clin Toxicol (Phila). 2010;48(9):953-955. doi:10.3109/15563650.2010.533676 [PubMed 21171855]
  100. Wu ML, Yang CC, Ger J, Tsai WJ, Deng JF. Acute hydrofluoric acid exposure reported to Taiwan Poison Control Center, 1991-2010. Hum Exp Toxicol. 2014;33(5):449-454. doi:10.1177/0960327113499165 [PubMed 23892993]
  101. Zaloga GP. Hypocalcemia in critically ill patients. Crit Care Med. 1992;20(2):251-262. [PubMed 1737459]
  102. Zenk KE. Management of intravenous extravasations. Infusion. 1981;5(4):77-79.
  103. Zhang Y, Wang X, Sharma K, et al. Injuries following a serious hydrofluoric acid leak: first aid and lessons. Burns. 2015;41(7):1593-1598. doi:10.1016/j.burns.2015.04.002 [PubMed 26188892]
  104. Zhang Y, Wang X, Ye C, et al. The clinical effectiveness of the intravenous infusion of calcium gluconate for treatment of hydrofluoric acid burn of distal limbs. Burns. 2014;40(4):e26-e30. doi:10.1016/j.burns.2013.12.003 [PubMed 24418646]
  105. Zhou P, Markowitz M. Hypocalcemia in infants and children. Pediatr Rev. 2009;30(5):190-192. doi:10.1542/pir.30-5-190 [PubMed 19411338]
Topic 9190 Version 368.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟